

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Osamu Nagayama
Inquiries to: Masahiko Uchida, General Manager,
Corporate Communications Dept.
Tel: +81-(0)3-3273-0881

Phase I Data of Chugai's Bispecific Antibody "ACE910" to be Presented at the American Society of Hematology Meeting

November 7, 2014 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that the Japanese phase I clinical data of anti-factor IXa x anti-factor X humanized bispecific antibody "ACE910," currently being developed for the indication of hemophilia A will be presented at the 56th American Society of Hematology (ASH) Annual Meeting held in San Francisco, CA from December 6 to 9.

This phase I trial is conducted with both healthy volunteers and hemophilia A patients. New data from the patients' part will be presented as an oral presentation at this meeting.

Overview of Presentation	Publication Number	Session Date
Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study	691	December 8

Access to the abstract of this presentation can be made via the following ASH website:

<https://ash.confex.com/ash/2014/webprogram/Paper67797.html>

Chugai co-develops the compound globally with F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan].